Biorasi’s Post

Great article on how technology can support greater #diversity in #clinicaltrials. This is a scientific, ethical, and regulatory imperative for sponsors. There are a number of practical steps that can be taken to impact trial diversity (enroll sites that serve the target populations, ensure participation from site staff from these populations, etc.), but here, Flatiron Health's Dr. Anosheh Afghahi demonstrates the role that #RWD can play in enhancing trial diversity. Check it out! At Biorasi, we're committed to partnering with our sponsors to deliver diverse trials. Great article, Dr. Afghahi.

To foster diversity and inclusion in the clinical research industry, building trust is absolutely critical. And making treatments effective and safe for all patients regardless of race, ethnicity, socioeconomic status, and other factors requires a multifaceted approach across the entire industry. In his latest piece for Forbes Technology Council, our CEO Gadi Saarony shares insights into why fear and mistrust of clinical trials still exists in many communities today, despite research being highly regulated, and how we can leverage technology to increase trust. Read it here: https://lnkd.in/epdza8kP #ClinicalResearch #ClinicalTrials #DEI

Our Chief Medical Officer, Dr. Fairooz Kabbinavar M.D., FACP, sat down with Clinical Leader to discuss a pivotal moment in Cardiff Oncology’s journey—our decision to transition our lead clinical development program from second-line to first-line RAS-mutated metastatic #colorectalcancer. In this Q&A, Dr. Kabbinavar shares the data that drove this decision, the collaborative conversations with the #FDA, and what this could mean for the future of mCRC treatment and patients. Interested in the strategy behind #clinicaltrial design? Then this interview is a must-read! https://lnkd.in/eMU-DemU #innovation #cancerresearch

Join us at the 2024 ASCO Annual Meeting on June 1 from 9:00 am-12:00 pm for a groundbreaking poster session on Efficient site selection for clinical trials using simulated annealing. This study identified sites with eligible patients for multi-site clinical trials using artificial intelligence solutions. With complex inclusion/exclusion criteria, limited resources, and the need for diversity in trials, the traditional site selection process can be quite challenging. However, this study has shown that AI can help optimize site selection to achieve enrollment, speed, and diversity goals. By translating clinical trial criteria into a digital form and utilizing a sophisticated algorithm, researchers were able to identify the most suitable sites for a Multiple Myeloma clinical trial. This innovative approach not only streamlines the site selection process but also addresses the challenges posed by complex protocols and the need for diverse study participants. Learn more: https://hubs.ly/Q02ypsv00 Authors: Ian Ruchlin, Vibhor Govil, Deepak Samar, Jitesh Chawla, Pyeush Gurha #OncologyResearch #ArtificialIntelligence #ClinicalTrials #ResearchInnovation #ASCO24

The Syneos Health 2025 Health Trends Report is live! This is where you can tap into the insights our experts at Syneos are pointing towards for the upcoming year. From the continued rise of artificial intelligence to the latest breakthroughs in precision medicine, this year’s Report uncovers the innovations that are transforming life sciences. Download the full report, register for our upcoming webinar and more: https://ow.ly/nYFm30sIPAp #SyneosHealth

🌟💬 Xtalks Spotlight: We spoke with Dr. Ieuan Clay, Director of Science at VivoSense, Inc., about integrating validated digital health technologies (#DHTs) into clinical research. With clinical trial costs ranging from $1 billion to $2 billion, timelines of 5-10 years, and success rates below 10%, the need for reform is clear. Dr. Clay highlights how DHTs can make trials faster, less costly, more patient-centric, and reflective of real-world outcomes. ⏩ Watch and read the full interview with Dr. Clay here: https://buff.ly/4bXY5oe #DigitalHealth #DigitalHealthTechnology #DigitalTechnologies #DigitalClinicalTrials #DigitalEndpoints

Join us tomorrow between 9:00 AM-12:00 PM CDT at the 2024 ASCO Annual Meeting for a groundbreaking poster session on Efficient site selection for clinical trials using simulated annealing. This study utilized artificial intelligence solutions to identify sites with eligible patients for multi-site clinical trials. Traditional site selection processes can be challenging due to complex inclusion/exclusion criteria, limited resources, and the need for diversity in trials. However, this study has shown that AI can optimize site selection to achieve enrollment, speed, and diversity goals. By translating clinical trial criteria into a digital form and using a sophisticated algorithm, researchers identified the most suitable sites for a Multiple Myeloma clinical trial. This innovative approach not only streamlines the site selection process but also addresses challenges posed by complex protocols and the need for diverse study participants. Learn more about this research at: https://hubs.ly/Q02z7J4Q0 #OncologyResearch #ArtificialIntelligence #ClinicalTrials #ResearchInnovation #ASCO24

Diversity in clinical trials isn’t optional—it’s essential. 🌍 Yet, systemic barriers often leave underrepresented groups out of critical medical research. At MyTrials.ai, we’re making a difference: 💡 AI-driven solutions to connect patients with the right trials 🤝 Community collaborations to foster trust and inclusion ✨ Streamlined participation to break down barriers Because when trials reflect the diversity of the real world, treatments become safer and more effective for everyone. Let’s build a healthcare future that truly represents us all. 💙 Blog: https://mytrials.ai/blog_4 #InclusiveResearch #DiversityInClinicalTrials #HealthForAll

Diversity in clinical trials is a game-changer for healthcare. Think about it—how can treatments work for everyone if the research doesn’t include everyone? (Spoiler: they can’t.) For years, barriers like access, mistrust, and strict eligibility rules have left many groups out. But here’s the good news: that’s starting to change. Platforms like MyTrials.ai are stepping up with AI-powered tools and strong community partnerships to make clinical trials more inclusive and accessible. This week, we’re breaking it all down—why diversity matters, what’s been holding us back, and how we’re making sure the future of medicine works for everyone.